Research pipeline · Not approved
OrforglipronOral non-peptide GLP-1 receptor agonist
Orforglipron is an investigational once-daily tablet from Eli Lilly. Unlike every licensed weight-management treatment, it is a small molecule rather than a peptide, which is what allows it to be taken orally without the absorption constraints peptides face. It is in late-stage trials, holds no marketing authorisation, and cannot lawfully be prescribed or supplied.
Not available
This compound is investigational. It holds no marketing authorisation from the MHRA, EMA or FDA, so it cannot lawfully be prescribed, sold or supplied for human use in the UK or elsewhere. Products offered online as "research use only" versions of it are unlicensed medicines, of unverified identity and purity, and are outside any clinical oversight.
At a glance
- Developer
- Eli Lilly
- Targets
- GLP-1
- Administration
- Once-daily tablet (in trials)
- Stage
- Phase 3 trials
- Reported
- Oral · ongoing
How Orforglipron differs
It is not a peptide. Peptide drugs are broken down in the digestive tract, which is why GLP-1 treatments are almost all injections. A small molecule survives oral administration, removing the injection entirely.
That matters for reasons beyond convenience: manufacturing a small molecule is not constrained by peptide synthesis capacity, which has been a limiting factor on supply across this whole category.
In Phase 2 it showed weight loss comparable to injectable agents. Whether that holds across the full Phase 3 programme is the open question.
Clinical evidence
What the trials showed
Weight loss comparable to injectable agents
A randomised Phase 2 trial reported substantial and sustained weight loss in adults with obesity, with efficacy in the range of injectable GLP-1 treatments.
Multiple trials ongoing
The Phase 3 programme includes trials in obesity with weight-related comorbidities and in maintenance of weight reduction, registered on ClinicalTrials.gov.
What is known about tolerability
- Gastrointestinal effects consistent with GLP-1 receptor agonism were the most commonly reported events in earlier trials.
- An oral route introduces its own considerations around absorption and dosing conditions, which late-stage trials are designed to characterise.
- No safety conclusions can be drawn ahead of regulatory review.
Availability
Not approved. The Phase 3 programme is ongoing. Orforglipron cannot be obtained lawfully for human use in the UK.
Orforglipron: Common questions
Is there a weight loss pill instead of an injection?
Not a licensed one for weight management in the UK. Orforglipron is an investigational once-daily tablet in late-stage trials, and it is a small molecule rather than a peptide, which is what makes oral dosing possible. It is not approved and cannot be prescribed.
Why are most weight loss treatments injections?
Because they are peptides, and peptides are broken down in the digestive tract before they can be absorbed. Injection bypasses that. Orforglipron is a small molecule rather than a peptide, which is why it can be given as a tablet.
Will there be a weight loss pill instead of injection?
Orforglipron is the candidate closest to it: a small-molecule GLP-1 receptor agonist taken orally, with no injection and no refrigeration. It is not approved, so there is no lawful supply, and an oral route does not by itself mean better tolerated — the gastrointestinal effects come from the mechanism rather than the needle. Whether it reaches the market, and at what efficacy, depends on trials that have not concluded.
Sources
- Orforglipron Phase 3 in obesity or overweight (NCT06972459) · ClinicalTrials.gov
- ATTAIN-MAINTAIN: orforglipron for maintenance of weight reduction (NCT06584916) · ClinicalTrials.gov
Awaiting sign-off by a named clinician.